Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Diagnosis & Therapy
Published in: Molecular Diagnosis & Therapy 1/2008

01-01-2008 | Cancer

Detecting and Treating Cancer with Nanotechnology

Authors: Keith B. Hartman, Professor Lon J. Wilson, Michael G. Rosenblum

Published in: Molecular Diagnosis & Therapy | Issue 1/2008

Login to get access

Abstract

Nanotechnology offers many opportunities for enhanced diagnostic and therapeutic medicine against cancer and other diseases. In this review, the special properties that result from the nanoscale size of quantum dots, metal colloids, superparamagnetic iron oxide, and carbon-based nanostructures are reviewed and interpreted against a background of the structural and electronic detail that gives rise to their nanotechnologic behavior. The detection and treatment of cancer is emphasized, with special attention paid to the biologic targeting of the disease. The future of nanotechnology in cancer research and clinical practice is projected to focus on ‘theranostic’ nanoparticles that are both diagnostic and therapeutic by design.
Literature
1.
2.
Agrawal A, Xing Y, Gao X, et al. Quantum dots. In: Vo-Dinh T, editor. Nanotechnology in biology: methods, devices, and applications. Boca Raton (FL): CRC Press, 2007: 1–15
3.
Klostranec JM, Chan WCW. Quantum dots in biological and biomedical research: recent progress and present challenges. Adv Mater 2006; 18(15): 1953–64CrossRef
4.
Caruthers SD, Wickline SA, Lanza GM. Nanotechnological applications in medicine. Curr Opin Biotechnol 2007; 18(1): 26–30PubMedCrossRef
5.
6.
Sonvico F, Dubernet C, Colombo P, et al. Metallic colloid nanotechnology, applications in diagnosis and therapeutics. Curr Pharm Design 2005; 11(16): 2091–105CrossRef
7.
Wang H, Brandl DW, Nordlander P, et al. Plasmonic nanostructures: artificial molecules. Acc Chem Res 2007; 40(1): 53–62PubMedCrossRef
8.
Duguet E, Vasseur S, Mornet S, et al. Magnetic nanoparticles and their applications in medicine. Nanomed 2006; 1(2): 157–68CrossRef
9.
Corot C, Robert P, Idee J-M, et al. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev 2006; 58(14): 1471–504PubMedCrossRef
10.
Tasis D, Tagmatarchis N, Bianco A, et al. Chemistry of carbon nanotubes. Chem Rev 2006; 106(3): 1105–36PubMedCrossRef
11.
Guldi DM, Rahman GMA, Sgobba V, et al. Multifunctional molecular carbon materials: from fullerenes to carbon nanotubes. Chem Soc Rev 2006; 35(5): 471–87PubMedCrossRef
12.
Hartschuh A, Pedrosa HN, Peterson J, et al. Single carbon nanotube optical spectroscopy. Chem Phys Chem 2005; 6(4): 577–82PubMedCrossRef
13.
Green M. Organometallic based strategies for metal nanocrystal synthesis. Chem Commun 2005; 24: 3002–11CrossRef
14.
Brus L. Electronic wave functions in semiconductor clusters: experiment and theory. J Phys Chem 1986; 90(12): 2555–60CrossRef
15.
Brus LE. Electron-electron and electron-hole interactions in small semiconductor crystallites: the size dependence of the lowest excited electronic state. J Phys Chem 1984; 80(9): 4403–9CrossRef
16.
Brachez Jr M, Moronne M, Gin P, et al. Semiconductor nanocrystals as fluorescent biological labels. Science 1998; 281(5385): 2013–6CrossRef
17.
Jaiswal JK, Mattoussi H, Mauro JM, et al. Long-term multiple color imaging of live cells using quantum dot bioconjugates. Nat Biotechnol 2003; 21(1): 47–51PubMedCrossRef
18.
Shepard JRE. Polychromatic microarrays: simultaneous multicolor array hybridization of eight samples. Anal Chem 2006; 78(8): 2478–86PubMedCrossRef
19.
Levy M, Cater SF, Ellington AD. Quantum-dot aptamer beacons for the detection of proteins. Chem Bio Chem 2005; 6(12): 2163–6PubMedCrossRef
20.
Chan P, Yuen T, Ruf F, et al. Method for multiplex cellular detection of mRN As using quantum dot fluorescent in situ hybridization. Nucleic Acids Res 2005; 33(18): e161/1–8CrossRef
21.
Ho Y-P, Kung MC, Yang S, et al. Multiplexed hybridization detection with multicolor colocalization of quantum dot nanoprobes. Nano Lett 2005; 5(9): 1693–7PubMedCrossRef
22.
Kobayashi H, Hama Y, Koyama Y, et al. Simultaneous multicolor imaging of five different lymphatic basins using quantum dots. Nano Lett 2007; 7(6): 1711–6PubMedCrossRef
23.
So M-K, Xu C, Loening AM, et al. Self-illuminating quantum dot conjugates for in vivo imaging. Nat Biotechnol 2006; 24(3): 339–43PubMedCrossRef
24.
Cai W, Shin D-W, Chen K, et al. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett 2006; 6(4): 669–76PubMedCrossRef
25.
Tada H, Higuchi H, Wanatabe TM, et al. In vivo real-time tracking of single quantum dots conjugated with monoclonal Anti-HER2 antibody in tumors of mice. Cancer Res 2007; 67(3): 1138–44PubMedCrossRef
26.
Yu X, Chen L, Li K, et al. Immunofluorescence detection with quantum dot bioconjugates for hepatoma in vivo. J Biomed Opt 2007; 12(1): 014008/1–5CrossRef
27.
Gao X, Chung LWK, Nie S. Quantum dots for in vivo molecular and cellular imaging. Meth Mol Biol 2007; 374 (Quantum Dots): 135–45
28.
Toms SA, Daneshvar H, Muhammad O, et al. Optical detection of brain tumors using quantum dots. Proceedings of the SPIE; 2005 Nov. In: Analoui M, Dunn DA, editors. Optical methods in drag discovery and development. Bellingham (WA): SPIE, 2005 [online]. Available from URL: http://​adsabs.​harvard.​edu/​abs/​2005SPIE.​6009.​.​125T [Accessed 2008 Feb 6]
29.
Chan WC, Nie S. Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science 1998; 281(5385): 2016–8PubMedCrossRef
30.
Ballou B, Lagerholm BC, Ernst LA, et al. Noninvasive imaging of quantum dots in mice. Bioconj Chem 2004; 15(1): 79–86CrossRef
31.
Akerman ME, Chan WCW, Laakkonen P, et al. Nanocrystal targeting in vivo. Proc Natl Acad Sci U S A 2002; 99(20): 12617–21PubMedCrossRef
32.
Grecco HE, Lidke KA, Heintzmann R, et al. Ensemble and single particle photophysical properties (two-photon excitation, anisotropy, FRET, lifetime, spectral conversion) of commercial quantum dots in solution and in live cells. Micro Res Tech 2004; 65(4/5): 169–79CrossRef
33.
Howarth M, Takao K, Hayashi Y, et al. Targeting quantum dots to surface proteins in living cells with biotin ligase. Proc Natl Acad Sci U S A 2005; 102(21): 7583–8PubMedCrossRef
34.
Pinaud F, King D, Moore H-P, et al. Bioactivation and cell targeting of semiconductor CdSe/ZnS Nanocrystals with phytochelatin-related peptides. J Am Chem Soc 2004; 126(19): 6115–23PubMedCrossRef
35.
Babu P, Sinha S, Surolia A. Sugar-quantum dot conjugates for a selective and sensitive detection of lectins. Bioconj Chem 2007; 18(1): 146–51CrossRef
36.
Sun X-L, Cui W, Haller C, et al. Site-specific multivalent carbohydrate labeling of quantum dots and magnetic beads. Chem Bio Chem 2004; 5(11): 1593–6PubMedCrossRef
37.
Gao X, Cui Y, Levenson RM, et al. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004; 22(8): 969–76PubMedCrossRef
38.
Goldman ER, Clapp AR, Anderson GP, et al. Multiplexed toxin analysis using four colors of quantum dot fluororeagents. Anal Chem 2004; 76(3): 684–8PubMedCrossRef
39.
Wu X, Liu H, Liu J, et al. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat Biotechnol 2003; 21(1): 41–6PubMedCrossRef
40.
Zhu L, Ang S, Liu W-T. Quantum dots as a novel immunofluorescent detection system for Cryptosporidium parvum and Giardia lamblia. Appl Environ Microbiol 2004; 70(1): 597–8PubMedCrossRef
41.
Soo Choi H, Liu W, Misra P, et al. Renal clearance of quantum dots. Nat Biotechnol 2007 Oct; 25(10): 1165–70CrossRef
42.
Jackson JB, Halas NJ. Silver nanoshells: variations in morphologies and optical properties. J Phys Chem B 2001; 105(14): 2743–6CrossRef
43.
Luo Y, Lee SK, Hofmeister H, et al. Pt nanoshell tubes by template wetting. Nano Lett 2004; 4(1): 143–7CrossRef
44.
Wang J, Zhu Y, Wu Y, et al. Fabrication, assembly and magnetic properties of nickel hollow nanoballs. Mod Phys Lett B 2006; 20(10): 549–55CrossRef
45.
Sershen SR, Westcott SL, Halas NJ, et al. Independent optically addressable nanoparticle-polymer optomechanical composites. Appl Phys Lett 2002; 80(24): 4609–11CrossRef
46.
Oldenburg SJ, Averitt RD, Westcott SL, et al. Nanoengineering of optical resonances. Chem Phys Lett 1998; 288(2,3,4): 243–7CrossRef
47.
Mohamed MB, Ismail KZ, Link S, et al. Thermal reshaping of gold nanorods in micelles. J Phys Chem B 1998; 102(47): 9370–4CrossRef
48.
Durr NJ, Larson T, Smith DK, et al. Two-photon luminescence imaging of cancer cells using molecularly targeted gold nanorods. Nano Lett 2007; 7(4): 941–5PubMedCrossRef
49.
Huang C-J, Wang Y-H, Chiu P-H, et al. Electrochemical synthesis of gold nanocubes. Mater Lett 2006; 60(15): 1896–900CrossRef
50.
Chen J, Saeki F, Wiley BJ, et al. Gold nanocages: bioconjugation and their potential use as optical imaging contrast agents. Nano Lett 2005; 5(3): 473–7PubMedCrossRef
51.
Hao F, Nehl CL, Hafner JH, et al. Plasmon resonances of a gold nanostar. Nano Lett 2007; 7(3): 729–32PubMedCrossRef
52.
Jain PK, Lee KS, El-Sayed IH, et al. Calculated absorption and scattering properties of gold nanoparticles of different size, shape, and composition: applications in biological imaging and biomedicine. J Phys Chem B 2006; 110(14): 7238–48PubMedCrossRef
53.
Gobin AM, Lee MH, Halas NJ, et al. Near-infrared resonant nanoshells for combined optical imaging and photothermal cancer therapy. Nano Lett 2007 Jul; 7(7): 1929–34PubMedCrossRef
54.
Copland JA, Eghtedari M, Popov VL, et al. Bioconjugated gold nanoparticles as a molecular based contrast agent: implications for imaging of deep tumors using optoacoustic tomography. Mol Imaging Biol 2004; 6(5): 341–9PubMedCrossRef
55.
Fu K, Sun J, Lin AWH, et al. Polarized angular dependent light scattering properties of bare and PEGylated gold nanoshells. Curr Nanosci 2007; 3(2): 167–70CrossRef
56.
Loo C, Hirsch L, Lee M-H, et al. Gold nanoshell bioconjugates for molecular imaging in living cells. Optics Lett 2005; 30(9): 1012–4CrossRef
57.
Hirsch LR, Stafford RJ, Bankson JA, et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci U S A 2003; 100(23): 13549–54PubMedCrossRef
58.
Overgaard K, Overgaard J. Investigations on the possibility of a thermic tumour therapy: I. Short-wave treatment of a transplanted isologous mouse mammary carcinoma. Eur J Cancer 1972; 8(1): 65–78PubMed
59.
Pankhurst QA, Connolly J, Jones SK, et al. Applications of magnetic nanoparticles in biomedicine. J Phys D Appl Phys 2003; 36(13): R167–81CrossRef
60.
Sershen SR, Westcott SL, Halas NJ, et al. Temperature-sensitive polymer-nanoshell composites for photothermally modulated drug delivery. J Biomed Mater Res 2000; 51(3): 293–8PubMedCrossRef
61.
Tartaj P, Morales MdP, Veintemillas-Verdaguer S, et al. The preparation of magnetic nanoparticles for applications in biomedicine. J Phys D Appl Phys 2003; 36(13): R182–97CrossRef
62.
Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterial 2005; 26(18): 3995–4021CrossRef
63.
Lee J, Isobe T, Senna M. Preparation of ultrafine Fe3O4 particles by precipitation in the presence of PVA at high pH. J Coll Inter Sci 1996; 177(2): 490–4CrossRef
64.
Massart R, Cabuil V. Effect of some parameters on the formation of colloidal magnetite in alkaline medium: yield and particle size control. J Chimie Physique Phys Chimie Biol 1987; 84(7–8): 967–73
65.
Pileni MP. Reverse micelles as microreactors. J Phys Chem 1993; 97(27): 6961–73CrossRef
66.
Zarur AJ, Ying JY. Reverse microemulsion synthesis of nanostructured complex oxides for catalytic combustion. Nature 2000; 403(6765): 65–7PubMedCrossRef
67.
Zhang Y, Kohler N, Zhang M. Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials 2002; 23(7): 1553–61PubMedCrossRef
68.
Pileni M-P. The role of soft colloidal templates in controlling the size and shape of inorganic nanocrystals. Nat Mater 2003; 2(3): 145–50PubMedCrossRef
69.
Reimer P, Balzer T. Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol 2003; 13(6): 1266–76PubMed
70.
Gruttner C, Teller J. New types of silica-fortified magnetic nanoparticles as tools for molecular biology applications. J Magn Magn Mater 1999; 194(1–3): 8–15CrossRef
71.
Berry CC, Curtis ASG. Functionalisation of magnetic nanoparticles for applications in biomedicine. J Phys D Appl Phys 2003; 36(13): R198–206CrossRef
72.
Ji X, Shao R, Elliott AM, et al. Bifunctional gold nanoshells with a superparamagnetic iron oxide-silica core suitable for both mr imaging and photothermal therapy. J Phys Chem C 2007; 111(17): 6245–51CrossRef
73.
Merbach AE, Toth E, editors. The chemistry of contrast agents in medical magnetic resonance imaging. New York: Wiley, 2001
74.
Mornet S, Vasseur S, Grasset F, et al. Magnetic nanoparticle design for medical diagnosis and therapy. J Mater Chem 2004; 14(14): 2161–75CrossRef
75.
Taupitz M, Wagner S, Schnorr J, et al. Phase I clinical evaluation of citrate-coated monocrystalline very small superparamagnetic iron oxide particles as a new contrast medium for magnetic resonance imaging. Invest Radiol 2004; 39(7): 394–405PubMedCrossRef
76.
Clement O, Siauve N, Cuenod CA, et al. Liver imaging with ferumoxides (Feridex): fundamentals, controversies, and practical aspects. Top Magn Reson Imaging 1998; 9(3): 167–82PubMedCrossRef
77.
Reimer P, Marx C, Rummeny EJ, et al. SPIO-enhanced 2D-TOF MR angiography of the portal venous system: results of an intraindividual comparison. J Magn Reson Imaging 1997; 7(6): 945–9PubMedCrossRef
78.
McLachlan SJ, Morris MR, Lucas MA, et al. Phase I clinical evaluation of a new iron oxide MR contrast agent. J Magn Reson Imaging 1994; 4(3): 301–7PubMedCrossRef
79.
Li W, Tutton S, Vu AT, et al. First-pass contrast-enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)-based blood pool agent. J Magn Reson Imaging 2005; 21(1): 46–52PubMedCrossRef
80.
Reimer P, Tombach B. Hepatic MRI with SPIO: detection and characterization of focal liver lesions. Eur Radiol 1998; 8(7): 1198–204PubMedCrossRef
81.
Schulze E, Ferrucci Jr JT, Poss K, et al. Cellular uptake and trafficking of a prototypical magnetic iron oxide label in vitro. Invest Radiol 1995; 30(10): 604–10PubMedCrossRef
82.
Toma A, Otsuji E, Kuriu Y, et al. Monoclonal antibody A7-superparamagnetic iron oxide as contrast agent of MR imaging of rectal carcinoma. Br J Cancer 2005; 93(1): 131–6PubMedCrossRef
83.
Funovics MA, Kapeller B, Hoeller C, et al. MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents. Magn Reson Imaging 2004; 22(6): 843–50PubMedCrossRef
84.
Tsourkas A, Shinde-Patil VR, Kelly KA, et al. In vivo imaging of activated endothelium using an anti-VCAM-1 magnetooptical probe. Bioconj Chem 2005; 16(3): 576–81CrossRef
85.
Josephson L, Tung C-H, Moore A, et al. High-efficiency intracellular magnetic labeling with novel superparamagnetic-tat peptide conjugates. Bioconj Chem 1999; 10(2): 186–91CrossRef
86.
Zhao M, Kircher Moritz F, Josephson L, et al. Differential conjugation of tat peptide to superparamagnetic nanoparticles and its effect on cellular uptake. Bioconj Chem 2002; 13(4): 840–4CrossRef
87.
Sun C, Sze R, Zhang M. Folic acid-PEG conjugated superparamagnetic nanoparticles for targeted cellular uptake and detection by MRI. J Biomed Mater Res A 2006; 78(3): 550–7PubMed
88.
Bos C, Delmas Y, Desmouliere A, et al. In vivo MR imaging of intravascularly injected magnetically labeled mesenchymal stem cells in rat kidney and liver. Radiology 2004; 233(3): 781–9PubMedCrossRef
89.
Frank JA, Miller BR, Arbab AS, et al. Clinically applicable labeling of mammalian and stem cells by combining superparamagnetic iron oxides and transfection agents. Radiology 2003; 228(2): 480–7PubMedCrossRef
90.
Leuschner C, Kumar CSSR, Hansel W, et al. LHRH-conjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases. Breast Cancer Res Treat 2006; 99(2): 163–76PubMedCrossRef
91.
Rosensweig RE. Heating magnetic fluid with alternating magnetic field. J Magn Magn Mater 2002; 252(1–3): 370–4CrossRef
92.
Jordan A, Rheinlaender T, Waldoefner N, et al. Increase of the specific absorption rate (SAR) by magnetic fractionation of magnetic fluids. J Nanopart Res 2003; 5(5–6): 597–600CrossRef
93.
Johannsen M, Gneveckow U, Taymoorian K, et al. Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: results of a prospective phase I trial. Int J Hyperthermia 2007; 23(3): 315–23PubMedCrossRef
94.
Kroto HW, Heath JR, O’Brien SC, et al. C60: buckminsterfullerene. Nature 1985; 318(6042): 162–3CrossRef
95.
96.
Dai H. Carbon nanotubes: synthesis, integration, and properties. Acc Chem Res 2002; 35(12): 1035–44PubMedCrossRef
97.
Cognet L, Tsyboulski DA, Rocha J-DR, et al. Stepwise quenching of exciton fluorescence in carbon nanotubes by single-molecule reactions. Science 2007; 316(5830): 1465–8PubMedCrossRef
98.
Cherukuri P, Bachilo SM, Litovsky SH, et al. Near-infrared fluorescence microscopy of single-walled carbon nanotubes in phagocytic cells. J Am Chem Soc 2004; 126(48): 15638–9PubMedCrossRef
99.
Cherukuri P, Gannon CJ, Leeuw TK, et al. Mammalian pharmacokinetics of carbon nanotubes using intrinsic near-infrared fluorescence. Proc Natl Acad Sci USA 2006; 103(50): 18882–6PubMedCrossRef
100.
Leeuw TK, Reith RM, Simonette RA, et al. Single-walled carbon nanotubes in the intact organism: near-IR imaging and biocompatibility studies in drosophila. Nano Lett 2007; 7(9): 2650–4PubMedCrossRef
101.
Kam NWS, O’Connell M, Wisdom JA, et al. Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proc Natl Acad Sci U S A 2005; 102(33): 11600–5PubMedCrossRef
102.
Gannon CJ, Cherukuri P, Yakobson BI, et al. Carbon nanotube-enhanced thermal destruction of cancer cells in a noninvasive radiofrequency field. Cancer 2007; 110(12): 2654–65PubMedCrossRef
103.
104.
Bolskar RD, Benedetto AF, Husebo LO, et al. First soluble M@C60 derivatives provide enhanced access to metallofullerenes and permit in vivo evaluation of Gd@C6o[C(COOH)2]io as a MRI contrast agent. J Am Chem Soc 2003; 125(18): 5471–8PubMedCrossRef
105.
Laus S, Sitharaman B, Toth E, et al. Destroying gadofullerene aggregates by salt addition in aqueous solution of Gd@C60(OH)x and Gd@C60[C(COOH2)]l0. J Am Chem Soc 2005; 127(26): 9368–9PubMedCrossRef
106.
Laus S, Sitharaman B, Toth E, et al. Understanding paramagnetic relaxation phenomena for water-soluble gadofullerenes. J Phys Chem C 2007; 111(15): 5633–9CrossRef
107.
Sitharaman B, Bolskar RD, Rusakova I, et al. Gd@C60[C(COOH)2]l0 and Gd@C60(OH)x: nanoscale aggregation studies of two metallofullerene MRI contrast agents in aqueous solution. Nano Lett 2004; 4(12): 2373–8CrossRef
108.
Toth E, Bolskar RD, Borel A, et al. Water-soluble gadofullerenes: toward high-relaxivity, pH-responsive MRI contrast agents. J Am Chem Soc 2005; 127(2): 799–805PubMedCrossRef
109.
Sitharaman B, Tran LA, Pham QP, et al. Gadofullerenes as nanoscale magnetic labels for cellular MRI. Contrast Media Molec Imag 2007; 2(3): 139–46CrossRef
110.
Fatouros PP, Corwin FD, Chen Z-J, et al. In vitro and in vivo imaging studies of a new endohedral metallofullerene nanoparticle. Radiology 2006; 240(3): 756–64PubMedCrossRef
111.
Rancan F, Helmreich M, Moelich A, et al. Synthesis and in vitro testing of a pyropheophorbide-a-fullerene hexakis adduct immunoconjugate for photodynamic therapy. Bioconj Chem 2007; 18(4): 1078–86CrossRef
112.
Ashcroft JM, Tsyboulski DA, Hartman KB, et al. Fullerene (C6o) immunoconjugates: interaction of water-soluble C60 derivatives with the murine anti-gp240 melanoma antibody. Chem Commun 2006; 28: 3004–6CrossRef
113.
Sitharaman B, Kissell KR, Hartman KB, et al. Superparamagnetic gadonanotubes are high-performance MRI contrast agents. Chem Commun 2005; 31: 3915–7CrossRef
114.
Sitharaman B, Wilson LJ. Gadonanotubes as new high-performance MRI contrast agents. Int J Nanomed 2006; 1(3): 291–5
115.
Hartman KB, Wilson LJ. Carbon nanostructures as a new, high-performance platform for MR molecular imaging. In: Chan WCW, editor. Bio-applications of nanoparticles. Austin (TX): Landes Biosciences, 2007
116.
Gu Z, Peng H, Hauge RH, et al. Cutting single-wall carbon nanotubes through fluorination. Nano Lett. 2002; 2(9): 1009–13CrossRef
117.
Hartman KB, Laus S, Bolskar RD, et al. Gadonanotubes as ultrasensitive pH-smart probes for magnetic resonance imaging. Nano Lett. Epub 2008 Jan 24
118.
Baselga J. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur J Cancer 2001; 37Suppl. 4: S16–22PubMedCrossRef
119.
Crombet T, Torres O, Rodriguez V, et al. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study. Hybridoma 2001; 20(2): 131–6PubMedCrossRef
120.
Labianca R, La Verde N, Garassino MC. Development and clinical indications of cetuximab. Int J Biol Markers 2007; 22(1 Suppl. 4): S40–6PubMed
121.
Morgillo F, Bareschino MA, Bianco R, et al. Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. Differentiation 2007 Nov; 75(9): 788–99PubMedCrossRef
122.
Yang XD, Jia XC, Corvalan JR, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001; 38(1): 17–23PubMedCrossRef
123.
Hudis CA. Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med 2007; 357(1): 39–51PubMedCrossRef
124.
Meric-Bernstam F, Hung M-C. Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin Cancer Res 2006; 12(21): 6326–30PubMedCrossRef
125.
Moasser MM. Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene 2007 Oct 11; 26(46): 6577–92PubMedCrossRef
126.
Simonds HM, Miles D. Adjuvant treatment of breast cancer: impact of monoclonal antibody therapy directed against the HER2 receptor. Expert Opin Biol Ther 2007; 7(4): 487–91PubMedCrossRef
127.
Inwards DJ, Cilley JC, Winter JN. Radioimmunotherapeutic strategies in autologous hematopoietic stem-cell transplantation for malignant lymphoma. Best Pract Res Clin Haematol 2006; 19(4): 669–84PubMedCrossRef
128.
Liebenguth P, Vogt Temple S. Radioimmunotherapy for non-Hodgkin’s lymphoma. Semin Oncol Nurs 2006; 22(4): 257–66PubMedCrossRef
129.
Schaefer-Cutillo J, Friedberg JW, Fisher RI. Novel concepts in radioimmunotherapy for non-Hodgkin’s lymphoma. Oncology 2007; 21(2): 203–12; discussion 214, 217, 221PubMed
130.
Witzig TE. Radioimmunotherapy for B-cell non-Hodgkin lymphoma. Best Pract Res Clin Haematol 2006; 19(4): 655–68PubMedCrossRef
131.
Fenton C, Perry CM. Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia. Drugs 2005; 65(16): 2405–27PubMedCrossRef
132.
Maslak PG, Jurcic JG, Scheinberg DA. Monoclonal antibody therapy of APL. Curr Top Microbiol Immun 2007; 313: 205–19CrossRef
133.
O’Brien S, Albitar M, Giles FJ. Monoclonal antibodies in the treatment of leukemia. Curr Molec Med 2005; 5(7): 663–75CrossRef
134.
135.
Pagano L, Fianchi L, Caira M, et al. The role of gemtuzumab ozogamicin in the treatment of acute myeloid leukemia patients. Oncogene 2007; 26(25): 3679–90PubMedCrossRef
136.
Tallman MS. New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents. Hematology Am Soc Hematol Educ Program 2005: 143–50
137.
Tsimberidou A-M, Giles FJ, Estey E, et al. The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol 2006; 132(4): 398–409PubMed
138.
Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005; 23(9): 1137–46PubMedCrossRef
139.
McDevitt MR, Chattopadhyay D, Kappel BJ, et al. Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. J Nucl Med 2007; 48(7): 1180–9PubMedCrossRef
140.
Mackeyev YA, Marks JW, Rosenblum MG, et al. Stable containment of radionuclides on the nanoscale by cut single-wall carbon nanotubes. J Phys Chem B 2005; 109(12): 5482–4PubMedCrossRef
141.
Hartman KB, Hamlin DK, Wilbur DS, et al. 211AtCl@US-tube nanocapsules: a new concept in radiotherapeutic-agent design. Small 2007; 3(9): 1496–9PubMedCrossRef
142.
Liu Z, Winters M, Holodniy M, et al. siRNA delivery into human T cells and primary cells with carbon-nanotube transporters. Angewandte Chem Int Ed 2007; 46(12): 2023–7CrossRef
143.
Jiang H, Zhang T, Sun X. Vascular endothelial growth factor gene delivery by magnetic DNA nanospheres ameliorates limb ischemia in rabbits. J Surg Res 2005; 126(1): 48–54PubMedCrossRef
144.
Dobson J. Gene therapy progress and prospects: magnetic nanoparticle-based gene delivery. Gene Ther 2006; 13(4): 283–7PubMedCrossRef
145.
Everts M, Saini V, Leddon JL, et al. Covalently linked Au nanoparticles to a viral vector: potential for combined photothermal and gene cancer therapy. Nano Lett 2006; 6(4): 587–91PubMedCrossRef
146.
Morishita N, Nakagami H, Morishita R, et al. Magnetic nanoparticles with surface modification enhanced gene delivery of HVJ-E vector. Biochem Biophys Res Commun 2005; 334(4): 1121–6PubMedCrossRef
147.
Portney NG, Ozkan M. Nano-oncology: drug delivery, imaging, and sensing. Anal Bioanal Chem 2006; 384(3): 620–30PubMedCrossRef
148.
Park JH, Kwon S, Nam J-O, et al. Self-assembled nanoparticles based on glycol chitosan bearing 5b-cholanic acid for RGD peptide delivery. J Control Release 2004; 95(3): 579–88PubMedCrossRef
149.
Chalasani KB, Russell-Jones GJ, Yandrapu SK, et al. A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin. J Control Release 2007; 117(3): 421–9PubMedCrossRef
150.
Cherian AK, Rana AC, Jain SK. Self-assembled carbohydrate-stabilized ceramic nanoparticles for the parenteral delivery of insulin. Drug Dev Ind Pharm 2000; 26(4): 459–63PubMedCrossRef
151.
Cui F-D, Tao A-J, Cun D-M, et al. Preparation of insulin loaded PLGA-Hp55 nanoparticles for oral delivery. J Pharm Sci 2007; 96(2): 421–7PubMedCrossRef
152.
Fernandez-Urrusuno R, Calvo P, Remunan-Lopez C, et al. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm Res 1999; 16(10): 1576–81PubMedCrossRef
153.
Gupta AK, Berry C, Gupta M, et al. Receptor-mediated targeting of magnetic nanoparticles using insulin as a surface ligand to prevent endocytosis. IEEE Trans Nanobiosci 2003; 2(4): 255–61CrossRef
154.
Leobandung W, Ichikawa H, Fukumori Y, et al. Preparation of stable insulin-loaded nanospheres of poly(ethylene glycol) macromers and N-isopropyl acrylamide. J Control Release 2002; 80(1–3): 357–63PubMedCrossRef
155.
Ma Z, Lim TM, Lim L-Y. Pharmacological activity of peroral chitosan-insulin nanoparticles in diabetic rats. Int J Pharm 2005; 293(1–2): 271–80PubMedCrossRef
156.
Ma Z, Yeoh HH, Lim L-Y. Formulation pH modulates the interaction of insulin with chitosan nanoparticles. J Pharm Sci 2002; 91(6): 1396–404PubMedCrossRef
157.
Mesiha MS, Sidhom MB, Fasipe B. Oral and subcutaneous absorption of insulin poly(isobutylcyanoacrylate) nanoparticles. Int J Pharm 2005; 288(2): 289–93PubMedCrossRef
158.
Pan Y, Li Y-J, Zhao H-Y, et al. Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int J Pharm 2002; 249(1–2): 139–47PubMedCrossRef
159.
Reis CP, Ribeiro AJ, Houng S, et al. Nanoparticulate delivery system for insulin: design, characterization and in vitro/in vivo bioactivity. Eur J Pharm Sci 2007; 30(5): 392–7PubMedCrossRef
160.
Sajeesh S, Sharma CP. Cyclodextrin-insulin complex encapsulated polymethacrylic acid based nanoparticles for oral insulin delivery. Int J Pharm 2006; 325(1–2): 147–54PubMedCrossRef
161.
Zhang Q, Shen Z, Nagai T. Prolonged hypoglycemic effect of insulin-loaded polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats. Int J Pharm 2001; 218(1–2): 75–80PubMedCrossRef
162.
Pan Y-L, Cai J-Y, Qin L, et al. Atomic force microscopy-based cell nanostructure for ligand-conjugated quantum dot endocytosis. Acta Biochim Biophys Sin 2006; 38(9): 646–52PubMedCrossRef
163.
Alexiou C, Jurgons R, Seliger C, et al. Delivery of superparamagnetic nanoparticles for local chemotherapy after intraarterial infusion and magnetic drug targeting. Anticancer Res 2007; 27(4A): 2019–22PubMed
164.
Fahmy TM, Fong PM, Park J, et al. Nanosystems for simultaneous imaging and drug delivery to T cells. AAPS J 2007; 9(2): E171–80PubMedCrossRef
165.
Gan ZF, Jiang JS, Yang Y, et al. Immobilization of homing peptide on magnetite nanoparticles and its specificity in vitro. J Biomed Mater Res A 2008 Jan; 84(1): 10–8PubMed
166.
Gupta AK, Naregalkar RR, Vaidya VD, et al. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Nanomed 2007; 2(1): 23–39CrossRef
167.
McCarthy JR, Kelly KA, Sun EY, et al. Targeted delivery of multifunctional magnetic nanoparticles. Nanomed 2007; 2(2): 153–67CrossRef
168.
Reddy GR, Bhojani MS, McConville P, et al. Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res 2006; 12(22): 6677–86PubMedCrossRef
169.
Serda RE, Adolphi NL, Bisoffi M, et al. Targeting and cellular trafficking of magnetic nanoparticles for prostate cancer imaging. Mol Imaging 2007; 6(4): 277–88PubMed
170.
Wang J-M, Xiao B-L, Zheng J-W, et al. Effect of targeted magnetic nanoparticles containing 5-FU on expression of bcl-2, bax and caspase 3 in nude mice with transplanted human liver cancer. World J Gastroenterol 2007; 13(23): 3171–5PubMed
171.
Zhang J, Misra RD. Magnetic drug-targeting carrier encapsulated with thermosensitive smart polymer: core-shell nanoparticle carrier and drug release response. Acta Biomater 2007; 3(6): 838–50PubMedCrossRef
172.
Xie H-Y, Zuo C, Liu Y, et al. Cell-targeting multifunctional nanospheres with both fluorescence and magnetism. Small 2005; 1(5): 506–9PubMedCrossRef
Metadata
Title
Detecting and Treating Cancer with Nanotechnology
Authors
Keith B. Hartman
Professor Lon J. Wilson
Michael G. Rosenblum
Publication date
01-01-2008
Publisher
Springer International Publishing
Published in
Molecular Diagnosis & Therapy / Issue 1/2008
Print ISSN: 1177-1062
Electronic ISSN: 1179-2000
DOI
https://doi.org/10.1007/BF03256264

Other articles of this Issue 1/2008

Molecular Diagnosis & Therapy 1/2008 Go to the issue

Commentary

Diagnostics for Aspirin Resistance

Neurological Disorders

NeuroAIDS

Diagnostic Profile

Aspirin Works®

News

From the World Literature

Original Research Article

TLR and MBL Gene Polymorphisms in Severe Acute Pancreatitis

Infectious Diseases

Rapid Diagnostics for Methicillin-Resistant Staphylococcus aureus
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits